CYP3A5 and neuropathy: McClain et al. (2016) performed a retrospective study with 239 Hispanic ALL patients, analyzing CYP3A5 extensive (*1/*1), CYP3A5 intermediate (*1/*3, *1/*6, *1/*7) and CYP3A5 poor metabolizers (*3/*3, *3/*6, *3/*7). No significant association was found between CYP3A5 polymorphisms and vincristine-induced peripheral neuropathy (VIPN). Skiles et al. (2018), included a cohort of 78 Kenyan children to find an association between CYP3A5 and VIPN. Ninety one percent of the children were CYP3A5 high-expresser genotypes and none developed neuropathy, leading to no conclusive results.